PharmaCyte Biotech(US:PMCB)2021-09-14 12:01Clinical Development - The company is focused on developing cellular therapies for cancer and diabetes using its proprietary Cell-in-a-Box technology[119]. - The Investigational New Drug Application (IND) for a planned Phase 2b clinical trial in locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) was submitted on September 1, 2020, but has been placed on clinical hold by the FDA[126][127]. - The FDA has requested additional studies and information, including genetic stability studies and a stability study on the final formulated drug product[128]. - The company is conducting a 3, 6, 9, and 12-month product stability study of its clinical trial product (CypCaps), with the next time point at 18 months[130]. - The company is exploring therapies for Type 1 diabetes and insulin-dependent Type 2 diabetes using encapsulated genetically modified insulin-producing cells[123]. - The COVID-19 pandemic has caused significant delays in clinical trials and has impacted the company's operations, particularly in preparing responses to the FDA's clinical hold[131][132]. - The company is in the process of updating its IND submission documents to include more pre-clinical data and additional parameters for the release of CypCaps[133]. - The company is conducting biocompatibility studies to demonstrate the safety and efficacy of CypCaps during delivery and use[130]. - The company has designed an abbreviated study in pigs to address biocompatibility and long-term implantation of the capsules, complementing previous human clinical trial data[133]. - The company is considering developing therapies for cancer involving prodrugs based on certain constituents of the Cannabis plant, but will not allocate resources until the clinical hold is lifted[125]. Financial Performance - The company reported no revenues for the three months ended July 31, 2021, consistent with the same period in 2020[138]. - Total operating expenses increased by $141,675 to $1,023,351 for the three months ended July 31, 2021, primarily due to a rise in general and administrative expenses[140]. - Net cash used in operating activities was $1,241,221 for the three months ended July 31, 2021, compared to $551,002 in the same period of 2020[143]. - As of July 31, 2021, the company's cash totaled approximately $959,000, down from approximately $2,167,000 at July 31, 2020[147]. - The company had no investing activities for the three months ended July 31, 2021 and 2020[145]. - The company plans to incur approximately $250,000 in costs related to service agreements for clinical trial preparations, with $162,000 allocated to related parties[150]. - The company experienced a decrease in total other expenses by $201, with interest expense increasing by $79 and income taxes rising by $800[142]. - The company had a working capital of approximately $583,000 as of July 31, 2021, down from approximately $1,116,000 at July 31, 2020[147]. - The company did not receive any funding from investors during the three months ended July 31, 2021, unlike the previous year when it raised funds through stock sales[148]. Risks and Challenges - The continuation of the COVID-19 pandemic poses risks to the company's clinical development program and overall operations, potentially affecting funding and supply chains[135].